Viking Therapeutics

VKTX Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$34.80

+5.58% today

52W: $18.92 – $43.15

52W Low: $18.92 Position: 65.5% 52W High: $43.15

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$4B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-47.34%

Return on Equity

Beta

0.82

Market sensitivity

Short Interest

25.09%

% of float sold short

Avg. Volume

2,959,552

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

18 analysts

Avg. Price Target

$92.72

+166.44% upside

Target Range

$35.00 – $125.00

About the Company

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 53 Exchange: NCM